Clinical Trial

Safety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this study is to evaluate the safety and efficacy of LX111 treatment of nAMD. This study will enroll subjects aged ≥ 50 vears old to receive a single unilateral intravitreal (lVT) injection of LX111 to evaluate its safety and efficacy.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-27; most recent amendment 2026-03-09.
Trial Details
NCT Number NCT07053358
Lead Sponsor Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Collaborators: Innostellar Biotherapeutics Co.,Ltd
Conditions Neovascular Age-related Macular Degeneration
Enrollment 10 participants
Start Date 2025-07-02
Primary Completion 2026-11-23 (estimated)
Study Completion 2029-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-10